IP Verse

Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof - EP3682905

The patent EP3682905 was granted to Moderna on Dec 1, 2021. The application was originally filed on Oct 3, 2012 under application number EP19216461A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3682905

MODERNA
Application Number
EP19216461A
Filing Date
Oct 3, 2012
Status
Granted And Under Opposition
Oct 29, 2021
Grant Date
Dec 1, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MAIWALDSep 1, 2022MAIWALDADMISSIBLE
PFIZERSep 1, 2022EDERADMISSIBLE
SANOFISep 1, 2022CARPMAELS & RANSFORDADMISSIBLE
SEQIRUS UKSep 1, 2022CARPMAELS & RANSFORDADMISSIBLE
WITHERS & ROGERSSep 1, 2022TOMBLINGADMISSIBLE
ETHERNA IMMUNOTHERAPIESAug 31, 2022ARNOLD & SIEDSMAADMISSIBLE
BIONTECHAug 29, 2022WILKADMISSIBLE
GLAXOSMITHKLINEAug 26, 2022WESTADMISSIBLE
PATENT BOUTIQUEJun 24, 2022PATENT BOUTIQUEADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 18, 2022WICHMANNADMISSIBLE

Patent Citations (80) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20100404413-
DESCRIPTIONUS2011177495
DESCRIPTIONUS2012237975
DESCRIPTIONUS4270537
DESCRIPTIONUS4596556
DESCRIPTIONUS4790824
DESCRIPTIONUS4886499
DESCRIPTIONUS4940460
DESCRIPTIONUS4941880
DESCRIPTIONUS5015235
DESCRIPTIONUS5064413
DESCRIPTIONUS5141496
DESCRIPTIONUS5190521
DESCRIPTIONUS5208020
DESCRIPTIONUS5312335
DESCRIPTIONUS5328483
DESCRIPTIONUS5334144
DESCRIPTIONUS5339163
DESCRIPTIONUS5383851
DESCRIPTIONUS5417662
DESCRIPTIONUS5466220
DESCRIPTIONUS5475092
DESCRIPTIONUS5480381
DESCRIPTIONUS5503627
DESCRIPTIONUS5520639
DESCRIPTIONUS5527288
DESCRIPTIONUS5569189
DESCRIPTIONUS5585499
DESCRIPTIONUS5599302
DESCRIPTIONUS5649912
DESCRIPTIONUS5704911
DESCRIPTIONUS5846545
DESCRIPTIONUS5893397
DESCRIPTIONUS5993412
DESCRIPTIONUS7893227
DESCRIPTIONWO2012045075
DESCRIPTIONWO2012045082
DESCRIPTIONWO9713537
DESCRIPTIONWO9737705
DESCRIPTIONWO9934850
OPPOSITIONEP2578685
OPPOSITIONEP2710136
OPPOSITIONEP2763701
OPPOSITIONEP2791160
OPPOSITIONEP2833922
OPPOSITIONEP3492109
OPPOSITIONEP3611266
OPPOSITIONEP3682905
OPPOSITIONUS2013245105
OPPOSITIONUS2014275227
OPPOSITIONWO2007024708
OPPOSITIONWO2007036366
OPPOSITIONWO2008083949
OPPOSITIONWO2011005799
OPPOSITIONWO2011071931
OPPOSITIONWO2012019168
OPPOSITIONWO2012030901
OPPOSITIONWO2012045075
OPPOSITIONWO2012045082
OPPOSITIONWO2012135805
OPPOSITIONWO2012158736
OPPOSITIONWO2013039861
OPPOSITIONWO2013052523
OPPOSITIONWO2013090648
OPPOSITIONWO2013096709
OPPOSITIONWO2013130161
OPPOSITIONWO2013151663
OPPOSITIONWO2013151664
OPPOSITIONWO2013151665
OPPOSITIONWO2013151666
OPPOSITIONWO2013151667
OPPOSITIONWO2013151668
OPPOSITIONWO2013151669
OPPOSITIONWO2013151670
OPPOSITIONWO2013151671
OPPOSITIONWO2013151672
OPPOSITIONWO2013151736
OPPOSITIONWO2014081507
OPPOSITIONWO2014152211
SEARCHWO2011012316

Non-Patent Literature (NPL) Citations (66) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALBRECHT, Immunotherapy, (20100000), vol. 2, no. 6, pages 795 - 8-
DESCRIPTION- ALTSCHUL, S. F. et al., J. Molec. Biol., (19900000), vol. 215, page 403-
DESCRIPTION- BERGE et al., Journal of Pharmaceutical Science, (19770000), vol. 66, pages 1 - 19-
DESCRIPTION- CARILLO, H.LIPMAN, D., SIAM J Applied Math., (19880000), vol. 48, page 1073-
DESCRIPTION- CARON et al., Mol Ther., (20010000), vol. 3, no. 3, pages 310 - 8-
DESCRIPTION- CHELLISERRYKATTILELLINGTON, Nature Biotechnology, (20040000), vol. 22, no. 9, pages 1155 - 1160-
DESCRIPTION- DESHAYES et al., Cell Mol Life Sci., (20050000), vol. 62, no. 16, pages 1839 - 49-
DESCRIPTION- DEVEREUX, J. et al., Nucleic Acids Research, (19840000), vol. 12, no. 1, page 387-
DESCRIPTION- EL-ANDALOUSSI et al., Curr Pharm Des., (20050000), vol. 11, no. 28, pages 3597 - 611-
DESCRIPTION- ESVELT et al., Nature, (20110000), vol. 472, no. 7344, pages 499 - 503-
DESCRIPTION- FUKUHARA et al., Biochemistry, (19620000), vol. 1, no. 4, pages 563 - 568-
DESCRIPTION- KARIKO K et al., Immunity, (20050000), vol. 23, pages 165 - 175-
DESCRIPTION- KARIKO K et al., Mol Ther, (20080000), vol. 16, pages 1833 - 40-
DESCRIPTION- MEYERSMILLER, CABIOS, (19890000), vol. 4, pages 11 - 17-
DESCRIPTION- MUSUNURU K et al., "From noncoding variant to phenotype via SORTI at the lp 13 cholesterol locus", Nature, (20100000), vol. 466, pages 714 - 721-
DESCRIPTION- OGATA et al., J. Org. Chem., (20090000), vol. 74, pages 2585 - 2588-
DESCRIPTION- OGATA et al., Journal of Organic Chemistry, (20090000), vol. 74, pages 2585 - 2588-
DESCRIPTION- "Oligonucleotide synthesis: methods and applications", Methods in Molecular Biology, Humana Press, (20050000), vol. 288-
DESCRIPTION- PADILLASOUSA, Nucleic Acids Research, (20020000), vol. 30, no. 24, page el28-
DESCRIPTION- PURMAL et al., Nucl. Acids Res., (19940000), vol. 22, no. 1, pages 72 - 78-
DESCRIPTION- PURMAL et al., Nucleic Acids Research, (19940000), vol. 22, no. 1, pages 72 - 78-
DESCRIPTION- Remington's Pharmaceutical Sciences, Mack Publishing Company, (19850000), page 1418-
DESCRIPTION- ROBBINS et al., Oligonucleotides, (20090000), vol. 19, pages 89 - 102-
DESCRIPTION- ROZENSKI, JCRAIN, PMCCLOSKEY, J., "The RNA Modification Database: 1999 update", Nucl Acids Res, (19990000), vol. 27, pages 196 - 197-
DESCRIPTION- T. HIGUCHIV. STELLA, "Pro-drugs as Novel Delivery Systems", A.C.S. Symposium Series, vol. 14-
DESCRIPTION- WARREN et al., Cell Stem Cell, (20100000), vol. 7, pages 618 - 630-
DESCRIPTION- XU et al., Tetrahedron, (19920000), vol. 48, no. 9, pages 1729 - 1740-
OPPOSITION- AGRIS et al., "Thermodynamic contribution of nucleoside modifications to yeast tRNA(Phe) anticodon stem loop analogs", Acta Biochimica Polonica, (19990000), vol. 46, pages 163 - 172, XP055959843-
OPPOSITION- Anonymous, "A-Plus™ Poly(A) Polymerase Tailing Kit ", Epicentre® Biotechnologies, (20061001), pages 1 - 3, XP055963394-
OPPOSITION- Anonymous, "mRNA-ONLY™ Prokaryotic mRNA Poly(A)-Tailing Kit", Epicentre® Biotechnologies, (20061001), pages 1 - 6, XP055963397-
OPPOSITION- BioRad, "Stocking up?", Reagents and Supplies Quick Reference Guide-
OPPOSITION- Brand Reindert C, Klootwijk Jacobus, Biochemischlaboratorium Rudi J Planta, Edward B, Maden H, " Biosynthesis of a Hypermodified Nucleotide in Saccharomyces carlsbergensis 17 S and HeLa-Cell 18 S Ribosomal Ribonucleic Acid", Biochem. J, (19780101), vol. 169, pages 71 - 77, XP055960175-
OPPOSITION- EARL et al., "A chemical synthesis of the nucleoside 1-methylpseudouridine", Division of Medicinal Chemistry, Department of Biopharmaceutical Sciences and Department of Chemistry, University of Utah, (19770600), pages 699 - 700, XP055959937-
OPPOSITION- Janeway, Jr. Ca, Travers P, Walport M Et Al., "Induced innate responses to infection ", Immunobiology: The Immune System in Health and Disease, 5th ed. - NCBI Bookshelf, (20010101), URL: https://www.ncbi.nlm.nih.gov/books/NBK27122/, XP055960605-
OPPOSITION- Karikó Katalin; Weissman Drew, "Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development.", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, GB , (20070101), vol. 10, no. 5, ISSN 1367-6733, pages 523 - 532, XP009154595-
OPPOSITION- Karikó Katalin, Weissman Drew, "Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development", Current opinion in drug discovery & development, (20070900), pages 523 - 532, XP009154595-
OPPOSITION- Ken J. Ishii, Shiyuo A Kira , "Nucleic Acids in Innate Immunity", Nucleic Acids in Innate Immunity, (20080101), XP055959634-
OPPOSITION- PANG et al., "Structure of a Modified Nucleoside in Archaebacterial tRNA Which Replaces Ribosylthymine. 1-Methylpseudouridine", The Journal of Biological Chemistry, (19820400), vol. 257, no. 7, pages 3589 - 3592, XP055959978-
OPPOSITION- Parham Peter, The Immune System, 3rd ed., (20090101), pages 49 - 50, ISBN 978-0-8153-4146-8, XP055960672-
OPPOSITION- REICHMAN et al., "Nucleosides. CVI. Syntheses of 1-N-methyl-5-(beta-D-ribofuranosyl)uracil (1-N-methyl-phi-uridine) and its identity with a metabolite elaborated by Streptomyces platensis var. clarensis", The Journal of Antibiotics, (19770200), vol. XXX, no. 2, pages 129 - 131, XP055959845-
OPPOSITION- WEISSMAN D, ET AL., "HIV GAG MRNA TRANSFECTION OF DENDRITIC CELLS (DC) DELIVERS ENCODED ANTIGEN TO MHC CLASS I AND II MOLECULES, CAUSES DC MATURATION, AND INDUCES A POTENT HUMAN IN VITRO PRIMARY IMMUNE RESPONSE", The Journal of Immunology, Williams & Wilkins Co., US, US , (20000101), vol. 165, no. 08, ISSN 0022-1767, pages 4710 - 4717, XP008051732-
OPPOSITION- Yarian Connie S. , Mufeed M. Basti, Robert J. Cain, Ghazala Ansari, Richard H. Guenther, Elzbieta Sochacka, Grazyna Czerwinska, Andrzej Malkiewicz, Paul F. Agris, "Structural and functional roles of the N1- and N3-protons of Ψ at tRNA's position 39", Nucleic Acids Research, (19990900), vol. 27, no. 17, pages 3543 - 3549, XP055959841-
OPPOSITION- Motorin Yuri, Helm Mark, "RNA nucleotide methylation", WIREs RNA, (20110900), vol. 2, no. 5, pages 611 - 631, XP055959997
OPPOSITION- Chang, Y.C. Herath, J. Wang, T.H.H. Chow, C.S., "Synthesis and solution conformation studies of 3-substituted uridine and pseudouridine derivatives", Bioorganic & Medicinal Chemistry, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20071119), vol. 16, no. 5, doi:10.1016/j.bmc.2007.11.039, ISSN 0968-0896, pages 2676 - 2686, XP022526163
OPPOSITION- Karikó Katalin, Buckstein Michael, Ni Houping, Weissman Drew, "Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA", Immunity, (20050800), vol. 23, no. 2, pages 165 - 175, XP055548954
OPPOSITION- Katalin Karikó, Michael Buckstein, Houping Ni, Drew Weissman, "Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20050801), vol. 23, no. 2, doi:10.1016/j.immuni.2005.06.008, ISSN 1074-7613, pages 165 - 175, XP055548954
OPPOSITION- Andries Oliwia, Mc Cafferty Séan, De Smedt Stefaan C., Weiss Ron, Sanders Niek N., Kitada Tasuku, "N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice", Journal of Controlled Release, (20150900), vol. 217, pages 337 - 344, XP055231071
OPPOSITION- Davis Frank F., Allen Frank Worthington, "RIBONUCLEIC ACIDS FROM YEAST WHICH CONTAIN A FIFTH NUCLEOTIDE", Journal of Biological Chemistry, (19570800), vol. 227, no. 2, pages 907 - 915, XP055959951
OPPOSITION- Kierzek Elżbieta, Kierzek Ryszard, "Influence of N6-isopentenyladenosine (i6A) on thermal stability of RNA duplexes", Biophysical Chemistry, (20010600), pages 135 - 140, XP055051202
OPPOSITION- KARIKÓ et al., "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability", Molecular Therapy, (20080000), vol. 16, no. 11, doi:10.1038/mt.2008.200, pages 1833 - 1840, XP055920956
OPPOSITION- KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.", Molecular Therapy, Nature Publishing Group, GB, GB , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0024, pages 1833 - 1840, XP002598556
OPPOSITION- Karikó Katalin, Muramatsu Hiromi, Welsh Frank A, Ludwig János, Kato Hiroki, Akira Shizuo, Weissman Drew, "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability", Molecular Therapy, (20081100), vol. 16, no. 11, pages 1833 - 1840, XP002598556
OPPOSITION- Karikó Katalin, Muramatsu Hiromi, Welsh Frank A, Ludwig János, Kato Hiroki, Akira Shizuo, Weissman Drew, "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability /NIH Author Manuscript/", Molecular Therapy, Elsevier Inc., US, US , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0016, pages 1833 - 1840, XP055920956
OPPOSITION- Karikó K, Muramatsu H, Keller J M, Weissman D., "Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.", Molecular Therapy, Nature Publishing Group, GB, GB , (20120501), vol. 20, no. 5, doi:10.1038/mt.2012.7, ISSN 1525-0024, pages 948 - 953, XP002696191
OPPOSITION- Züst Roland, Cervantes-Barragan Luisa, Habjan Matthias, Maier Reinhard, Neuman Benjamin W, Ziebuhr John, Szretter Kristy J, Baker Susan C, Barchet Winfried, Diamond Michael S, Siddell Stuart G, Ludewig Burkhard, Thiel Volker, "Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5", Nature Immunology, (20110200), vol. 12, no. 2, pages 137 - 143, XP037065924
OPPOSITION- Sahin Ugur, Karikó Katalin, Türeci Özlem, "mRNA-based therapeutics — developing a new class of drugs", Nature Reviews Drug Discovery, (20140900), vol. 13, no. 10, pages 759 - 780, XP037134862
OPPOSITION- Ugur Sahin, Katalin Karikó, Özlem Türeci, "mRNA-based therapeutics — developing a new class of drugs", Nature Reviews Drug Discovery, Nature Pub. Group, vol. 13, no. 10, doi:10.1038/nrd4278, ISSN 14741776, pages 759 - 780, XP055159205
OPPOSITION- Robbins Marjorie, Judge Adam, Liang Lisa, Mcclintock Kevin, Yaworski Ed, Maclachlan Ian, "2′-O-methyl-modified RNAs Act as TLR7 Antagonists", Molecular Therapy, (20070900), vol. 15, no. 9, pages 1663 - 1669, XP002590543
OPPOSITION- Motorin Yuri, Lyko Frank, Helm Mark, "5-methylcytosine in RNA: detection, enzymatic formation and biological functions", Nucleic Acids Research, (20091200), vol. 38, no. 5, pages 1415 - 1430, XP055681117
OPPOSITION- B. R. Anderson, H. Muramatsu, B. K. Jha, R. H. Silverman, D. Weissman, K. Kariko, "Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L", Nucleic Acids Research, Information Retrieval Ltd., (20111101), vol. 39, no. 21, doi:10.1093/nar/gkr586, ISSN 03051048, pages 9329 - 9338, XP055126203
OPPOSITION- Katalin Karikó, Hiromi Muramatsu, János Ludwig, and Drew Weissman, "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.", Nucleic Acids research, Oxford University Press, GB, GB , (20111101), vol. 39, no. 21, doi:10.1093/nar/gkr695, ISSN 1362-4962, pages e142 - e142-10, XP002696190
OPPOSITION- Tcherepanova Irina Y; Adams Melissa D; Feng Xiaorong; Hinohara Atsushi; Horvatinovich Joe; Calderhead David; Healey Don; Nicolette Charles A, "Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion", BMC MOLECULAR BIOLOGY, GB , (20081017), vol. 9, no. 1, doi:10.1186/1471-2199-9-90, ISSN 1471-2199, page 90, XP021042442
OPPOSITION- Chatterjee Kunal, Blaby Ian K., Thiaville Patrick C., Majumder Mrinmoyee, Grosjean Henri, Yuan Y. Adam, Gupta Ramesh, De Crécy-Lagard Valérie, "The archaeal COG1901/DUF358 SPOUT-methyltransferase members, together with pseudouridine synthase Pus10, catalyze the formation of 1-methylpseudouridine at position 54 of tRNA", RNA, (20120300), vol. 18, no. 3, pages 421 - 433, XP055959943
OPPOSITION- SCHLAKE T, THESS A, FOTIN-MLECZEK M, KALLEN K-J, "Developing mRNA-vaccine technologies", RNA BIOLOGY, (20121101), vol. 9, no. 11, doi:10.4161/rna.22269, ISSN 1547-6286, pages 1319 - 1330, XP002743467
SEARCH- LUIGI WARREN ET AL, "Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA", vol. 7, no. 5, doi:10.1016/J.STEM.2010.08.012, ISSN 1875-9777, (20101105), pages 618 - 630, CELL STEM CELL, CELL PRESS, UNITED STATES, URL: http://www.sciencedirect.com/science/article/pii/S1934590910004340, XP002693059 [A] 1-11 * abstract *
SEARCH- KARIK� KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 11, doi:10.1038/MT.2008.200, ISSN 1525-0024, (20081101), pages 1833 - 1840, (20080916), XP002598556 [A] 1-11 * abstract; figure 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents